Life sciences software vendor Medidata is collaborating with US-based Moderna on clinical trials of its Covid-19 vaccine, mRNA-1273.

Moderna is planning to launch its Phase III trial of mRNA-1273 in 30,000 patients this month. The company will leverage Medidata’s suite of Rave technology to support virtualisation of the trial to speed up data capture and reduce the need for burdensome patient site visits.

Medidata co-founder and co-CEO Tarek Sherif said: “We are proud to be working with Moderna on these breakthrough trials, which are so important to medical science and the health of our global society.

“The extensive partnership we’ve built together over many years is allowing us to support these critical clinical studies. Clearly, the faster we can arrive at answers, the better it will be for everyone, everywhere.”

Moderna chief digital and operational excellence officer Marcello Damiani added: “We are pleased to collaborate with Medidata.

“Medidata’s unified platform is helping us put participants at the centre of our efforts to develop a safe and effective vaccine against Covid-19.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.